CliffBio
small molecule

DAURISMO

GLASDEGIB MALEATE

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAURISMO
Active ingredientGLASDEGIB MALEATE
StrengthEQ 100MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11168066April 2036use U-3254
11891372April 2036use U-3254
10414748April 2036substance, product
8148401November 2032substance, product
8431597June 2028product

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAURISMO patent cliff — loss of exclusivity April 2036 | CliffBio